secwatch / observer

Daily 8-K Digest — 2026-08-13

Generated August 13, 2026 at 8:30 PM ET · Covers August 13 trading day · 10 of 352 ready 8-Ks selected · AI-assisted overview

The day's filings were dominated by M&A and corporate actions. Accelerant Holdings agreed to be acquired by Thoma Bravo in a $4B all-cash deal, while Digital Asset Acquisition Corp. terminated its merger with Old Glory and postponed its meeting. Vireo Growth closed the PharmaCann Colorado acquisition and secured an $85M credit facility. Several regulatory and compliance updates were also notable: Nutex Health highlighted a Fifth Circuit ruling on insurance payment rules, Nocera regained Nasdaq compliance, and Sagimet received FDA clearance for a Phase 3 trial. On the financial side, Pelthos restated Q1 results and reported a Q2 loss, while Nano Nuclear reported strong cash and progress on its reactor program. Artius II Acquisition announced liquidation, and Atlantic International settled a dispute with Circle8, canceling a $35M note.
DAAQ Digital Asset Acquisition Corp.
M&A negative materiality 0.90 August 13, 2026, 5:02 PM ET

Digital Asset Acquisition Corp. terminates merger with Old Glory; meeting postponed

  • Mutual termination of Business Combination Agreement dated Jan 13, 2026, effective Aug 13, 2026.
  • Extraordinary general meeting scheduled for Aug 14, 2026 indefinitely postponed due to no business.
  • No termination fee payable; each party bears its own expenses per Termination Agreement.
ARX Accelerant Holdings
M&A positive materiality 1.00 August 13, 2026, 7:57 AM ET

Accelerant to be acquired by Thoma Bravo for $20.25/share (49% premium); Q2 EWP up 23%

  • All-cash deal valued at >$4B enterprise value; shareholders get $20.25/share, 49% premium to Aug 12 close.
  • Expected close H1 2027; Altamont (82% voting) supports; no financing condition; shares to delist from NYSE.
  • Q2: Exchange Written Premium $1.32B (+23% YoY); net income $80M, EPS $0.36; adjusted EPS $0.32 (+146%).
VREOF Vireo Growth Inc.
M&A positive materiality 0.85 August 13, 2026, 7:00 AM ET

Vireo closes PharmaCann Colorado acquisition (17 stores) and secures $85M BMO credit facility

  • Acquired PharmaCann Colorado retail assets for ~$48.7M: 3,004,751 subordinate voting shares plus assumed liabilities; 17 dispensaries added, footprint now 56 in Colorado.
  • New $85M asset-based revolving credit facility with Bank of Montreal, expandable to $105M, maturing Aug 7, 2031; SOFR+1.75-2.00% or base+0.75-1.00%.
  • Proceeds to refinance existing Chicago Atlantic debt and shareholder notes, fund working capital, capex, and permitted acquisitions.
NUTX Nutex Health Inc.
regulatory positive materiality 0.75 August 13, 2026, 4:01 PM ET

Fifth Circuit vacates NSA ghost-rate and bonus-exclusion rules; Nutex Health to benefit from higher QPA

  • On Aug 11, 2026, en banc Fifth Circuit in Texas Medical Association v. HHS vacated July 2021 Rule allowing ghost rates and excluding bonus/incentive payments from QPA.
  • Court ruled insurers must include bonus and incentive payments and cannot use non-negotiated placeholder rates; vacatur upheld with enforcement discretion for existing QPAs until new rules.
  • Ruling cites ghost rates suppressed QPA and led IDR arbitration awards exceeding QPA in 85% of cases.
NCRA NOCERA, INC.
regulatory positive materiality 0.65 August 13, 2026, 5:00 PM ET

Nocera regains Nasdaq compliance; sells Alabama land for $700k

  • Sold 231 acres in Montgomery County, AL to Timothy and Catherine Rudder for $700k cash; net proceeds ~$654,604 after ~$42,175 in closing costs.
  • Property book value was ~$877,870; expects ~$178k loss on sale in Q3 2026.
  • Nasdaq confirmed compliance with Listing Rule 5550(b) based on Q2 10-Q showing stockholders' equity of $5,435,030; matter closed.
SGMT Sagimet Biosciences Inc.
regulatory positive materiality 0.60 August 13, 2026, 7:05 AM ET

FDA clears IND for Sagimet's denifanstat Phase 3 acne trial

  • FDA issued 'Study May Proceed' letter for Phase 3 trial of denifanstat in moderate to severe acne.
  • Denifanstat is a fatty acid synthase inhibitor; trial cleared on August 13, 2026.
  • Sagimet announced the IND clearance, enabling initiation of the Phase 3 study.
PTHS Pelthos Therapeutics Inc.
earnings negative materiality 0.90 August 13, 2026, 7:15 AM ET

Pelthos restates Q1 2026 financials; Q2 net loss $23.4M, Zelsuvmi revenue up 45% QoQ

  • Restating Q1 2026 (March 31) financials; prior statements no longer reliable per Item 4.02.
  • Q2 2026 net loss $(23.4)M vs $(25.1)M Q1; adjusted EBITDA $(5.7)M vs $(8.0)M.
  • Zelsuvmi net revenue $15.4M, up 45% QoQ; 11,925 units dispensed by 4,571 prescribers.
AACB Artius II Acquisition Inc.
other material negative materiality 0.95 August 13, 2026, 8:00 AM ET

Artius II Acquisition to liquidate, redeem public shares after failing to close business combination

  • Board decided Aug 13, 2026 to liquidate and dissolve; will cease all operations except winding up.
  • Public shares redeemed at cash per-share equal to trust account balance (net of taxes and up to $100k expenses) divided by outstanding shares.
  • Rights included in IPO units will expire worthless; no redemption rights or liquidating distributions for rights.
NNE Nano Nuclear Energy Inc.
earnings positive materiality 0.85 August 13, 2026, 4:05 PM ET

NANO Nuclear reports Q3 FY26: NRC accepts KRONOS CPA, STS acquisition, $580M cash

  • NRC docketed CPA for KRONOS MMR at University of Illinois; expects environmental assessment Q1 2027, safety evaluation Q3 2027.
  • Completed acquisition of Secured Transportation Systems (STS); STS 2025 audited revenue $7.1M, net income $1.3M; $3.9M unaudited revenue H1 2026.
  • Cash, cash equivalents, and short-term investments total $580M as of June 30, 2026; raised $26M via ATM during Q3.
ATLN ATLANTIC INTERNATIONAL CORP.
other material positive materiality 0.90 August 13, 2026, 5:23 PM ET

Circle8 settles SPP dispute, cancels $35M convertible note; gets Nasdaq bid price deficiency

  • Settlement with SPP extinguishes $35M convertible seller's note due March 2027; resolves NY and DE litigation.
  • Atlantic issues ~21.98M new shares to SPP; SPP grants 10-yr call option to repurchase same shares at $0.00001 each for retirement.
  • SPP to sell shares over ~18 months to repay $62.67M indebtedness; remaining shares returned if repaid early.
Generated from SEC 8-K filings received on 2026-08-13. Not investment advice. · Live feed · Executive changes · All-filings RSS · Methodology
Item-code hubs covered today: · 1.01 · 1.02 · 2.01 · 2.02 · 2.03 · 3.01 · 3.02 · 4.02 · 7.01 · 8.01 · 9.01